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1. Introduction 
 
Although there have been significant improvements in the treatment of 
cardiovascular diseases they still remain the main cause of morbidity and 
mortality globally. Increased burden of cardiovascular diseases on both 
individuals and societies has led governments and health care professionals 
to invest more avidly on preventive measurements. Primary prevention 
includes early diagnosis and treatment of the disease and risk stratifications 
before diseases are in advanced stages and thus require costly and often 
invasive therapeutic approaches.  
Traditionally, in cardiovascular medicine, the diagnosis, monitoring of the 
progression of disease and the evaluation of therapeutic effects are 
accomplished by studying the anatomy and the physiological consequences 
manifested as changes in flow, metabolism and function of the heart and/or 
blood vessels. However, in early disease stages these approaches may not 
be adequate to detect pathologic changes, therefore the ability to image 
noninvasively pathophysiologic processes on a molecular level is thought to 
provide an opportunity in the future to enhance the diagnostic capabilities. 
Techniques for molecular imaging have been developed for essentially all 
forms of medical imaging.  These techniques generally involve the 
formulation of novel site-targeted contrast agents with the goal of detecting 
the molecular footprint specific for a particular disease state. 
The application of molecular imaging technologies is currently in preclinical 
research. Translation of these approaches to the clinical field may provide 
additional information on the molecular and pathophysiological process of 
disease and possibly a mean to personalize approaches for the evaluation 
and management of disease. ! !
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1.1. Definition of Molecular imaging 
 
Molecular imaging can be defined as the visualization, characterization and 
noninvasive measurement of a biological process at a molecular and cellular 
level. Molecular imaging technologies have been developed over the past two 
decades, initially using nuclear imaging techniques. Subsequently, molecular 
imaging technologies have been developed for all other imaging methods 
available including computed tomography (CT) imaging, magnetic resonance 
(MR) imaging, optical fluorescence and bioluminescence imaging and also for 
ultrasound based imaging. All these methods have in common that they use a 
contrast agent that is targeted to a specific molecule present in the tissue. 
The use of a contrast agent for molecular imaging requires interaction and 
retention of the agent with an endogenous molecule (1). Potential clinical and 
research applications of molecular imaging methods are summarized in figure 
1 (2). 
 
 
 
Although molecular imaging has been developed for almost all forms of 
medical imaging modalities, there are significant differences in terms of 
spatial resolution, sensitivity and practicability between different detection 
methods (ultrasound, gamma radiation detector, magnetic resonance, light 
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and ect.). Differences in the properties of the imaging probes additionally 
influence relative toxicity, sensitivity, specificity, biodistribution and temporal 
resolution of the images. Table 1 presents selected operational parameters 
for different imaging modalities. High sensitivity, availability, relatively low cost 
and rapid imaging execution protocols are properties of molecular imaging 
with ultrasound detectors that make ultrasound molecular imaging particularly 
interesting for screening large numbers of patients for potential diseases 
including cardiovascular disorders (3).  
 
Table 1. Comparison of molecular imaging technologies. Adapted from Sinusas AJ 
et al. Multimodality cardiovascular molecular imaging, Part I. Circ Cardiovasc 
Imaging. 2008 Nov;1(3):244-56(1). PET represents positron emission tomography 
and SPECT, single photon emission computed tomography.  
Imaging modality 
Spatial 
resolution 
Depth of 
penetration 
Temporal 
resolution 
Sensitivity 
(mol/L) 
PET 1-2 mm No limit Sec-min 10-11 -10-12 
SPECT 0.3-1 mm No limit min 10-10 -10-11 
MRI 50-250 µm  No limit Min-hrs 1013 -10-5 
X-ray CT 25-150 µm No limit min No data 
Ultrasound 30-500 µm mm-cm Sec-min 10-6 -10-9 
 
 
 
 
 
! 8!
 
1.2 Contrast enhanced ultrasound molecular imaging !
A wide spectrum of non- invasive molecular imaging techniques to evaluate 
the phenotype of diseased tissue in vivo has been developed. The use of 
these methods in research and in the clinical field may overcome the 
shortcomings of traditional imaging modalities, which evaluate anatomy or 
physiology of the organs. The application of these techniques in 
cardiovascular diseases may improve our understanding of pathophysiology 
of the disease, diagnose life-threatening disease at early stages, monitor 
disease progression, assess response to novel and established therapies and 
finally select appropriate therapies according to the phenotype of the disease. 
Contrast Enhanced Ultrasound (CEU) molecular imaging is among these 
newly developed imaging modalities that have been of interest to both 
clinicians and researchers. CEU molecular imaging relies on selective 
targeting and retention of imaging probes at the site of disease.  So to better 
understand this imaging technique it is worthwhile to discuss 1) the properties 
of contrast agents and for the ultrasound imaging 2) the physical properties of 
ultrasound waves and 3) contrast-specific ultrasound imaging protocols. 
 
1.2.1 Contrast agent 
 
The main requirements for ultrasound contrast agents are that they should be 
easy to administer to the circulatory system, be stable enough throughout the 
duration of image acquisition, have low toxicity and finally provide the highest 
possible contrast-to-tissue ratio of acoustic reflection. The use of gas bubbles 
to enhance the blood pool for ultrasound imaging goes back to 1968 when 
Gramiak and Shah during echocardiography injected agitated normal saline 
into the ascending aorta. They could detect strong echoes in the aorta and 
the heart chambers. They concluded that these strong echoes were due to 
the air bubbles, formed by agitation or cavitation during injection(4). In 1984 
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Feinstein et al produced albumin encapsulated microbubbles by sonication of 
human serum albumin and showed that these could be visualized in the left 
ventricle after intravenous injection (5).  
Since then, ultrasound contrast agents have been developed and approved 
by regulatory authorities for various clinical applications such as left ventricle 
cavity opacification (Figure 2) or characterization of liver masses by 
assessing vascular filling patterns. These contrast agents are gas-filled 
microbubbles, which are smaller than red blood cells (RBC) and therefore are 
able to circulate freely in the vasculature, and thus are called ‘ blood pool’ 
agents. Contrast agents act by either their presence in the circulation (‘blood 
pool’ agents) or by their selective retention or uptake by cells following a 
vascular phase(6). 
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Microbubbles are composed of a shell and a gas core. The shell is composed 
of albumin, lipids or biocompatible polymers. The shell increases the stability 
of the contrast agents by decreasing the gas volume loss, reducing surface 
tension and additionally controls the size distribution during the production 
process. The microbubble shell is thin and measure between 3 nanometers in 
lipid-encapsulated and 20 nanometers in albumin-encapsulated agents and 
therefore eventually will allow a diffusible gas such as air to leak out and 
return to the blood resulting in a relatively short half life of air-filled 
microbubbles. Therefore instead of air many manufacturers take advantage 
of gases with a high molecular weight and low solubility properties 
(perflurocarbones, sulfur-hexafluroride). The low diffusion rate results in an 
increased half-life of microbubbles in the circulation (6).  
Ultrasound contrast agents currently in use vary in size from several hundred 
nanometers to a few micrometers in diameter. The size of the acoustic 
particles determines their stability in the circulation, their passage through the 
pulmonary capillary network necessary for reaching the systemic circulation, 
and their acoustic properties. For clinical use contrast agents are 
microbubbles with a mean diameter in the range of 2-3µm. These blood pool 
agents are characterized by flow dynamics similar to red blood cells and 
eventually are taken up by the reticuloendothelial system where they are 
metabolized by liver Kupffer cells (6).  
Lipid shelled microbubbles have several specific properties that make them 
interesting for clinicians and researchers. Phospholipids spontaneously 
assemble in monolayers at gas-water interfaces. Phospholipids are ideal 
agents for the microbubble shell as they can oscillate, that is to say expand 
and compress during insonification. Finally, lipid shells of microbubbles can 
be easily functionalized for molecular imaging or drug delivery by 
incorporating various lipid head group species into the shell that can be used 
for the attachment of targeting ligands (7). 
To increase the longevity of lipid shelled microbubbles in circulation, 
polyethylenglycol (PEG) compounds are also incorporated into the  
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microbubble shell. The exact physical basis of the increased half life of PEG 
microbubbles in vivo as well as the mechanism of interaction of the PEG 
microbubbles with cells is not yet fully understood. It has been shown that in 
the presence of a PEG brush on the surface of microbubbles, hydrostatic and 
electrostatic interactions between microbubbles and plasma proteins such as 
complement components will decrease (8,9). Decreased deposition of 
complement on the surface of PEG microbubbles in turn decreases the 
uptake of mircobbbles by the reticuloendothelial system and might be 
responsible for the longer half life of microbubbles (10,11). However recently 
it has been demonstrated that PEG does little to inhibit deposition of 
complement on microbubble surface but provides a steric barrier to 
interaction of complement deposited on microbubbles with endothelial cell 
surface receptors (12,13).  
 
1.2.2 Ultrasound 
 
Ultrasound waves are sound waves with higher frequencies than audible 
sound. Audible sound wave frequencies range from 20 hertz (Hz) to 20,000 
Hz( 20 kHz). Any sound wave with frequencies above 20 KHz is not audible 
for the human ear and is referred to as ultrasound. In medical imaging, 
alternating electricity-induced deformation of a piezoelectric element is used 
to generate ultrasound waves. The piezoelectric element not only transmits 
the ultrasound wave but also receives returned echoes reflected by the tissue 
interfaces. In clinical imaging applications the frequencies in use range 
between 2-15 MHz although frequencies up to 40 MHz may also be used for 
special applications.  
A sound wave is a longitudinal wave consisting of cyclic pressure variations. 
As sound travels it causes the particles in its path to be displaced in the 
direction of the wave propagation. The speed of the propagation of sound is 
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determined by the stiffness and density of a media it is travelling in. The 
ultrasound wavelength is defined as the distance of two identical consecutive  
points on a sinusoidal curve describing the cyclic pressure variations of the 
ultrasound wave.  The wavelength can be calculated by dividing the speed of 
sound in a specific media by the original frequency of the source of sound 
(Figure 3). The wavelength of the ultrasound determines the image 
resolution, a shorter wavelength results in a higher image resolution.  
 
 
 
A specific property of an ultrasound wave, as opposed to an audible sound 
wave, is that it can be sent from the ultrasound source into a specific 
direction. The amplitude of the sound wave is represented by the maximum 
pressure variations above and below the baseline measured in pressure units 
(megapascals; MPa)(Figure 4). The amount of energy that can be transferred 
to tissue per unit of time is defined as the power of the ultrasound beam. The 
power per cross section area of the beam reflects the intensity of the beam. 
The intensity increases when 1) the power increases or 2) when there is a 
decrease in the cross section area of the beam by adjusting the focus of the 
ultrasound beam. The estimated peak intensity at the focal point of the 
ultrasound beam is represented by the Mechanical Index (MI) derived from 
the average peak negative pressure of the beam (P) divided by the square 
root of the transmitted frequency (f):  
MI=P/√f 
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As ultrasound travels through the tissue the intensity and amplitude of the 
beam decreases, a phenomenon named attenuation, which is measured in 
dB. Attenuation occurs predominantly due to the absorption of the ultrasound 
beam in tissue. Attenuation depends on the distance travelled and also the 
frequency of ultrasound, where attenuation is larger for higher frequencies.  
 
 
 
 
In soft tissue the average propagation speed of ultrasound is 1540 m/ s. It is 
higher in less compressible media such as bone and lower in more 
compressible media such as air. The propagation speed is used to determine 
the distance of a structure from the source of the wave and confines it in an 
appropriate location on the formed image (Figure 5). 
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While the ultrasound wave is travelling through the tissue it encounters 
different interfaces with different acoustic properties, which will influence the 
propagation. Propagation also depends on the angle of incidence (θi) of the 
beam to the interface. When encountering an interface between two 
structures with different acoustic properties, a part of the ultrasound wave is 
reflected and returns toward the source of sound and the reminder is 
refracted. The proportion of reflected or scattered sound waves that travels 
back to the source of sound (scan head) is used to generate the image of the 
examined structure (Figure 6).  
 
 
 
 
! 15!
 
 
 
 
Eventually as ultrasound is a compression wave (MI dependent mechanical 
effects) and is absorbed by the tissue (Thermal index heating effect) it can 
interact with the tissue. Ultrasound at high intensity doses can cause 
immediate thermal and mechanical effects at the time of exposure.  However 
the long term effects of high intensity ultrasound on humans is not yet clear. 
Therefore the safety of using ultrasound in medical imaging is of 
consideration. According to international safety requirements the MI and TI of 
the ultrasound should be displayed on the ultrasound systems and in the 
case of requiring MI or TI above curtain levels benefits from ultrasound 
examinations should be weighed against its risks.   
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1.2.3 Contrast specific ultrasound imaging 
 
When microbubbles are exposed to an ultrasound field they expand during 
the peak negative portion of the ultrasound beam and were compressed 
during positive peak portion. The ideal resonant frequency of microbubbles is 
close to frequencies that are used for clinical imaging. Therefore when 
microbubbles are exposed to the ultrasound beam they resonate efficiently. 
Unlike tissue, when microbubbles are exposed to various amplitude sounds 
they behave in different ways. At lower incident pressures bubbles produce 
linear backscatter, which can be used to enhance echo from blood. At higher 
incident pressures beyond 50-100 kPa backscatters from bubbles show 
nonlinear characteristics. These properties of bubbles were used to develop 
contrast specific imaging protocols such as harmonic and pulse inversion 
imaging modes (see below). When the incident pressure exceeds about 1 
MPa, bubbles for a short time emit non-linear backscatter and soon after will 
be destroyed.  !
1.2.4 Linear backscatter  
 
Although bubbles are smaller than red blood cells and their concentration in 
blood after intravenous injection is small when compared to red blood cells, 
the amplitude of the backscattered echo from microbubbles is several orders 
of magnitude larger than backscattered signal from red blood cells. This can 
be explained by the mismatch in acoustic impedance (which itself is 
influenced by the density and compressibility of the object) between the 
bubble gas core and blood, and the efficient resonance properties of 
microbubbles when exposed to ultrasound frequencies used in clinical 
equipment. This mismatch in acoustic impedance permits signal 
enhancement in ultrasound imaging. 
Thus, in fundamental frequency gray scale imaging, signal enhancement from 
microbubble contrast agents can be detected in the lumina of the ventricles or 
large vessels where the concentration of bubbles is high enough. However, in 
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the case of the imaging of smaller myocardial vessels the contrast is not 
normally detectable due to high echogenicity of the myocardium itself. Thus, 
in order to further increase the contrast-to-tissue signal difference, 
microbubble-specific imaging techniques have been developed. 
 
1.2.5 Non-linear backscatter: Harmonic imaging 
 
As microbubbles in the ultrasound beam are subjected to low-pressures (less 
than 100 kPa or MI of less than 0.1) they start to resonate and undergo 
compression and rarefaction phases around their radius in harmony with the 
cyclic pressure variations of the ultrasound wave. Ultrasound signal emitted 
by bubbles at this pressure is received by the transducer at the same 
frequency as the incident beam. Such frequencies are called fundamental 
frequency. If microbubbles are driven by a sufficiently large acoustic pressure 
(more than 100 kPa or MI of more than 0.1) they reach a point where the 
cyclic expansion and compression does not occur linearly anymore, but 
rather asymmetric. Thus the frequencies of the emitted echoes from bubbles 
are not the same as incident frequencies but exact multiples of the 
fundamental frequency. These frequencies are named harmonic frequencies 
(6). This non- linear response of microbubbles in the ultrasound beam can be 
used to distinguish the signal of contrast agent from surrounding tissue 
(Figure7). 
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To increase the signal from contrast agent to the noise from tissue one 
strategy would be subtraction of background acquired from precontrast 
frames. The resulting frame reflects only the signal from contrast agent (14).  
!!
 1.2.6 Non- linear backscatter: Pulse inversion imaging 
 
In harmonic imaging, the transmitted frequencies should be set close to the 
band around fundamental frequencies while received frequencies should be 
restricted to the second harmonic frequencies of contrast agent. This setting 
limits image resolution from contrast agent because of restricted bandwidth.  
Therefore to overcome the conflict between the requirements of contrast 
detection and resolution in harmonic imaging and to surpass the signal from 
tissue, pulse inversion protocols have been developed and implemented on 
ultrasound scanners.   
This method also relies on non-linear oscillation of bubbles in the ultrasound 
field. However it detects all nonlinear components of echoed sound including 
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second harmonics over the entire bandwidth of the transducer. In this method 
two successive sound pulses are transmitted into the tissue. The second 
pulse is a mirror image of the first pulse. The transducer receives the echoes 
of these pulses and sums them up. If the ultrasound pulses are reflected from 
tissue, due to the linear behavior of tissue the sum of the pulses will cancel 
out.  However, microbubbles will behave non-linearly in response to the same 
ultrasound pulses which will be changed and backscattered asymmetrically 
and therefore when summed will not equal zero. Thus the signal from 
microbubbles will be detected by the scanner but not the signal from tissue 
(Figure 8). One advantage of pulse inversion protocol over harmonic imaging 
is that the transducer receives a complete bandwidth of the reflected 
ultrasound. This allows forming a high-resolution image from bubbles in real 
time (15).  
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1.2.7 Non-linear backscatter: Power modulation 
 
At low power imaging, signal to noise ratio could also be increased by using a 
power modulation technique. In this method instead of using two pulses with 
different acoustic phases, two pulses with different acoustic power or 
amplitude are used. A first pulse would be transmitted at low power and the 
second at very low power, at half the amplitude of the first pulse. During 
image processing the echoes from the second pulse are doubled in amplitude 
and subtracted from the first pulse. Therefore, the echoes from tissue will be 
canceled due to linear behavior of tissue under low power ultrasound waves. 
In contrast, the signal from bubbles will not be nullified as bubbles behave 
nonlinearly in low power pulses but not at very low power pulses (Figure 9).  
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1.3 Targeting of contrast agent for moelcular imaging 
 
Molecular imaging with contrast- enhanced ultrasound relies on selective 
retention of targeted microbubbles at the site of disease. It is important to 
note that contrast agents, whether they are microbubbles or larger-sized 
nanoparticles, are entirely intravascular agents and they do not leave the 
vascular compartment (16,17). Therefore to image pathophysiological 
processes microbubbles are targeted either to disease specific molecules 
expressed on the endothelial cells, blood cell components (activated 
leukocytes or platelets) or blood proteins such as fibrin(13,18-23). However, 
nanoparticles, because of their relatively smaller size and longer circulation 
times, in the regions where vascular permeability is disrupted would leak out 
and would be able to target extravascular components (24). 
There are two general strategies to target contrast agents: 1) non- specific 
targeting and 2) specific targeting. 
A simple approach for microbubble targeting is to take advantage of the 
innate properties of the shell of microbubbles to bind directly or indirectly to 
pathologically activated cells. This technique relies on the composition of 
albumin or lipid shell microbubbles (17,25-28). For example incorporating 
anionic phospholipids into the lipid shell of the microbubbles has been shown 
to amplify complement-mediated attachment of microbubbles to activated 
leukocytes in regions of inflammation (25,27,28) or to the complement 
receptors on the endothelium (13). This approach can be further modified by 
alternating the amount of steric hindrance from polyethylenglycol (PEG) in the 
shell composition (13). Albumin microbubbles additionally have the ability to 
bind to the β2-integrins on activated leukocytes that recognize denatured 
albumin(25) 
A more specific approach for microbubble targeting is the conjugation of 
target-specific ligands on the microbubble surface. This can be achieved 
either directly by covalent binding or indirectly by non-covalent links to the 
microbubble surface. The applied method depends on the nature of the 
microbubble surface (29). Functionalized polyethylenglycol spacer arms 
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consisting of a phospholipid tail, which is incorporated into the lipid shell, a 
spacer part to project the ligand above the shell surface and an active 
chemical group are used for the conjugation process (figure 10) (30).  
 
 
 
 
Biotin-Avidin- biotin interaction is an example of a non-covalent bond, which 
is commonly used for targeting purposes of contrast agents in vitro and 
selected pre-clinical in vivo settings (Figure 11). Avidin has a high affinity for 
biotin and forms stable and strong bonds between biotinylated ligand and 
biotin- functionalized PEG spacer arms incorporated into the shell of the 
contrast agent under physiologic conditions (29). However, translation of this 
approach to clinical settings is limited due to the immunogenicity of avidin. 
! 23!
Avidin is generally extracted from bacterial sources or white egg, which is a 
foreign protein and may have clinical limitations, particularly if it is used 
repeatedly. In addition avidin is a cationic macromolecule, which immediately 
forms in situ immunocomplexes when exposed to anionic sites within 
glomerular base membrane (31). Therefore, for clinical applications of 
ultrasound molecular imaging, other conjugation methods for targeting 
ligands will have to be established. For example small peptides can be 
covalently bound to PEG spacer arms functionalized by maleimide groups on 
the microbubble surface(29). 
 
 
 
 
Conjugation may be performed before or after preparation of the contrast 
agent depending on the properties of the ligand used and its tolerance to the 
chemical processing required for producing the contrast agent. Generally, 
several hundred to several thousand ligands per square micron of shell 
surface area can be conjugated to the contrast agent.  
 !
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1.4 Targeting and molecular imaging in large arteries 
 
Several factors play a role for successful molecular imaging. The targeted 
molecule should be specific for the disease and should not be expressed 
constitutively on a large scale. As attachment of the contrast agent occurs 
under vascular flow, shear rate in the tissue of interest and bond affinity 
between the ligand on the contrast agent and the targeted molecule (on- and 
off-rate) are two factors with significant roles. In addition, ligand density on 
the contrast agent and site density of the targeted molecule are two other 
influencing factors that should be considered  (Figure 12)(2,3). 
As mentioned above, vascular shear rate is one of the factors influencing the 
extent of attachment of targeted microbubbles in arteries, where shear stress 
is high. CEU molecular imaging with antibody bearing targeted microbubbles 
has been successfully performed in the microvasculature of the myocardium, 
kidney and skeletal muscles where shear rate is low (around 3-5 dynes/cm2) 
(32-34). However, in large arteries such as the mouse aorta, shear rate is 
much higher with shear rate around 80 to 90 dynes/cm2 (35,36). Given the 
low bond formation rate (low on rate) of antibody targeted microbubbles, 
successful attachment under high shear rate flows could be explained by the 
pulsatile nature of arterial flow. During diastole arterial flow rate is near zero 
thus bonds between targeted microbubbles and their endothelial target will 
form. These bonds are strong enough to endure high shear rates during 
systole. Flow chamber studies have demonstrated that under constant high 
flow the attachment of targeted microbubbles will dramatically decrease 
(19,37). In contrast, simulations of pulsatile flow have illustrated that short 
interruptions of flow result in the attachment of targeted microbubbles. 
Resumption of flow did not cause detachment of microbubbles indicating the 
strength of the formed bonds (low off rate) (19).  Regarding potential clinical 
applications, it should be mentioned that the wall shear rate in larger arteries 
in humans is lower compared to small animal models. Therefore attachment 
efficiency in humans should be better or similar to small animals (38). 
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1.5 Detection of targeted microbubbles: Imaging strategies 
 
Since generation of signal from microbubbles relies on their oscillation in the 
acoustic field it is important to know how this oscillation might be influenced 
by targeting of microbubbles and their subsequent attachment to the cells. 
There are two separate scenarios that should be considered. If targeted 
microbubbles are attached and phagocytized by activated leukocytes they are 
more stable when exposed to ultrasound energy and it is more difficult to 
destroy them. However they oscillate less efficiently and generate a smaller 
amplitude signal compared to freely circulating microbubbles (27,39). On the 
other hand, it has been shown that attachment of targeted microbubbles to a 
cell surface such as endothelial cells, will improve stability of microubbles 
over time without damping the signal (40,41).  
To image attached targeted microbubbles with ultrasound in the tissue of 
interest, the strategy is to wait some minutes after the bolus injection of 
microbubbles. This waiting time is adequate for the formation of ligand- 
counter ligand bonds on the endothelium and for the uptake of part of freely 
circulating microbubbles by the reticuloendothelial system. After this time 
acquiring images with high MI will resume. High MI imaging is then used 
throughout the image acquisition. The first acquired frame reflects the signal 
from both attached and freely circulating microbubbles. Imaging will continue 
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by acquiring several short pulse interval frames to destroy attached 
microbubbles. Afterwards, a few long pulse interval frames will also be 
recorded. These frames represent the signal from freely circulating 
microbubbles, which keep flowing into the region of interest. Subtraction of 
the signal intensity from the averaged post-destruction frames from the initial 
pre-destruction frame will reflect the signal from retained microbubbles in the 
region of interest. This strategy is also illustrated on figure 13. 
 
 
 !!!!
! 27!
1.6 Advantages and disadvantages of ultrasound based- 
imaging 
 
As mentioned before, molecular imaging has been developed for almost all 
types of imaging modalities available. The application of each imaging 
modality for a specific disease is influenced by different factors. Determinant 
factors could be sought in the type of detector and used contrast agent. In 
contrast enhanced ultrasound molecular imaging, microbubbles do not leave 
the vascular compartment thus limiting the potential targets into the 
vasculature. Additionally microbubble targeting and successful attachment 
follows the same rules as those for cell attachment. Therefore their 
attachment only happens at certain expression threshold of targeted 
molecules on the endothelial surface. However ultrasound based molecular 
imaging has some major advantages. First, in ultrasound molecular imaging 
there is a good balance between spatial resolution and the sensitivity of the 
technique in detecting the contrast agent. Second, the designed imaging 
protocols are relatively short and they can be completed in a period of 10 to 
20 minutes. These are major characteristics, which programs implemented to 
screen large population would probably take advantage of. In addition 
Ultrasound molecular imaging could be of use in the fast detection of 
diseases such as coronary artery diseases, where time plays a critical role. 
 
1.7 Atherosclerosis 
 
Atherosclerosis is the main cause of coronary artery disease, cerebrovascular 
accidents and peripheral vascular disease, and consequently it represents 
the most common cause of morbidity and mortality globally. Atherosclerosis 
involves medium and large size arteries and is characterized by patchy 
subintimal infiltrates of the arterial wall. Fatty streaks are the earliest visible 
lesions of atherosclerosis and consist of lipid-laden foam cells accumulating 
in the intimal layer of arteries. Over time these lesions will evolve to fibrotic 
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plaques encroaching into the arterial lumen. Plaques may become unstable 
resulting in plaque rupture and thrombotic occlusion of an artery.  The extent 
of inflammation, oxidized lipid content, protease activation, plaque 
neovascularization and thrombus formation determine atherosclerotic plaque 
stability (42). 
Inflammation plays a crucial role in the pathophysiology of atherosclerosis 
both in the initiation and progression of the disease. Biologically active 
species such as oxidized Low Density Lipoprotein (LDL), reactive oxygen 
species, and advanced glycation end products initiate the atherosclerotic 
process by stimulating vascular endothelial cells to produce and express 
inflammatory molecules. Inflammatory molecules such as Intercellular 
Adhesion Molecule (ICAM), Vascular Cell Adhesion Molecule (VCAM-1) and 
P-selectin facilitate the recruitment of inflammatory cells including monocytes 
and T cells into the vessel walls by mediating interactions between leukocytes 
and the endothelium (43-45). Inflammatory cells promote smooth muscle cell 
migration and further recruitment of leukocytes by producing reactive oxygen 
species, vasoactive peptides, prothrombotic compounds, cytokines and pro-
angiogenic growth factors (43). Therefore VCAM-1, ICAM-1 and/ or P-selctin 
could be used as potential markers for early detection of atherosclerosis.  
 
1.8 CEU imaging in atherosclerosis 
 
Ultrasound detection and enhancement of pathologic components of 
atherosclerosis could be achieved by targeting contrast agents to endothelial 
molecular markers of atherosclerotic lesions. Early in vitro studies 
demonstrated successful attachment of targeted microbubbles to ICAM-1 
expressed on activated endothelial cells indicating the potential application of 
diagnostic ultrasound in characterizing cell phenotype (46).  
First in vivo studies to assess the feasibility of ultrasound molecular imaging 
in detecting atherosclerosis encompassed application of intravascular 
ultrasound (IVUS) and intra-
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To create various stages of atheroma, yucatan miniswine carotid and femoral 
endothelial layers were injured and animals were kept on high-cholesterol 
diet. It was illustrated that there is a selective enhancement of molecular 
components of atheroma and injured endothelium by targeting liposomes to 
VCAM-1, ICAM-1, TF and fibrin. This allowed to better characterize the type 
and extent of atherosclerotic lesion progression (21). However, the invasive 
nature of IVUS imaging and required high doses of intra-arterial injected 
liposomes to produce signal above the background signal are a drawback in 
clinical translation of this method.  
In another study to evaluate vascular inflammatory processes in 
atherosclerosis, non-invasive ultrasound molecular imaging using 
microbubbles was applied in a mouse model of atherosclerosis deficient for 
Apo-E lipoprotein. Given the fact that endothelial expression of VCAM-1 is 
up-regulated throughout the pathogenesis of atherosclerosis, microbubbles 
were targeted to VCAM-1. Contrast Enhanced Ultrasound imaging of the 
aortic arch demonstrated signal enhancement for microbubbles targeted to 
VCAM-1 but not for control microbubbles in atherosclerotic animals with 
advanced lesions. In contrast, no signal enhancement for microbubbles 
targeted to VCAM-1 was seen in control wild type animals that do not develop 
atherosclerosis. Therefore, CEU molecular imaging of VCAM-1 could non-
invasively assess the degree of the development of atherosclerosis (19). 
Likewise, CEU molecular imaging in atherosclerotic mice with genetic 
deletion for LDL receptor and apolipoprotein(Apo) mRNA editing protein 
Apobec-1 (LDLR-/-/Apobec-1-/- ) could detect  lesion-prone vascular 
phenotype before the appearance of advanced atheromas. The study showed 
an increased signal for VCAM-1 and P-selectin targeted microbubbles in 
ultrasound imaging at a timepoint when histologic studies demonstrated only 
mild regional vascular wall thickening consistent with very early stages of 
atherosclerosis.  Accordingly the signal intensities at different age points were 
comparable with plaque development on histology (47).   
 CEU Molecular imaging has also been used to detect high-risk 
atherosclerotic phenotype by detecting activated von Willebrand Factor (vWF) 
on the vascular endothelium. Vascular collagen exposure to the circulation 
! 30!
due to endothelial injury can cause conformational activation and adherence 
of vWF to endothelial cells. Interaction of vWF and activated platelets via 
glycoprotein-Ibα (GP- Ibα) can initiate events that lead to thrombotic 
complications of atherosclerosis. Thus targeting of microbubbles to activated 
vWF by surface conjugation of GP- Ibα has been used to trace thrombotic- 
prone atheromas in LDLR-/-/Apobec-1-/- mice.  On CEU, signal from vWF 
targeted microbubbles in the aortic arch of the atherosclerotic mice was 
significantly higher compared to the signal from wild type mice. En face 
microscopy of the aortic arch of the atherosclerotic mice also demonstrated 
co-localization of regions with adhered platelets and vWF microbubbles(42).  
The aforementioned studies displayed the feasibility of CEU in non-invasively 
assessing atherosclerotic disease severity by targeting contrast agents to 
endothelial molecular components of atherosclerosis. As an extension of the 
spectrum of the use of molecular imaging in atherosclerosis, assessment of 
the response to drug treatment is of interest. 
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2. Aims of the PhD project 
The overall aim of this PhD project was to (1) investigate the influence 
of microbubble shell characteristics on targeting efficiency, and (2) to 
establish, whether ultrasound molecular imaging can be used to assess 
anti-inflammatory treatment effects of drugs in relevant murine models 
of atherosclerosis. 
 
2.1 Specific Aim 1 
To investigate the influence of the length of functionalized polyethylene 
glycol spacer arms incorporated in microbubble shell on improving the 
targeting efficiency of microbubbles 
Polyethylene glycol tethers bearing a biotin molecule at their tip are used for 
attaching ligands for molecular imaging to the microbubble surface using a 
biotin-streptavidin-biotin link.  The length of the polyethylene glycol tethers 
determines how far the ligands project away from the microbubble surface.  
Whether the length of polyethylene glycol tethers for ligand attachment 
influences attachment efficiency to molecular targets has never been 
examined. In addition, this effect may differ between molecular targets, as for 
example P-Selectin is a relatively long molecule that projects far away from 
the endothelial cell surface above the glycocalix, whereas ICAM-2 is a shorter 
molecule. Therefore in this research project we aimed to optimize the length 
of the polyethylene glycol tethers of the microbubble shell for targeted 
microbubble attachment to endothelial cells.   
 
2.2 Specific Aim 2 
To assess the feasibility of noninvasive ultrasound molecular imaging 
in detecting anti-inflammatory effect of statins in early murine 
atherosclerosis 
Atherosclerosis is a chronic inflammatory disorder. Therefore therapies aimed 
at interrupting inflammatory signalling mechanisms or the inciting deposition 
of oxidized LDL in the vessel wall are being used therapeutically or being 
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investigated (48).  HMG-CoA reductase inhibitors (statins) have been shown 
to reduce VCAM-1 expression in experimental atherosclerosis (49,50) 
independent of the effect on cholesterol, and have been studied extensively 
for primary and secondary prevention of cardiovascular events in clinical trials 
(51,52). A method to noninvasively assess the reduction of VCAM-1 and 
other markers of inflammation in response to HMG-CoA might potentially be 
of use in assessing the adequacy of HMG-CoA dosing regimens.  More 
importantly, non-invasive molecular imaging of the expression of VCAM-1 
may be useful for selecting patients for emerging anti-inflammatory therapies 
and assessing the response to these agents. Therefore our aim was to 
assess the feasibility of ultrasound molecular imaging in detecting a reduction 
in endothelial expression of VCAM-1 in response to HMG-CoA.  
 
2.3 Specific Aim 3 
To investigate the short-term effects of treatment with apocynin on 
endothelial inflammation and thrombogenicity in a murine model of 
early atherosclerosis- application of ultrasound molecular imaging 
Reactive Oxygen Species (ROS) have been attributed a key role in the 
inflammatory processes that lead to atherosclerosis. ROS products may also 
influence vascular thrombogenicity. Hence, there is an interest in antioxidant 
drugs as a treatment option.  Apocynin is a small molecule that has been 
shown to inhibit endothelin-1-mediated VCAM-1 expression in the carotid 
arteries of hypertensive rats (53).  Thus, our aim was to assess whether non-
invasive ultrasound molecular imaging could detect the therapeutic effects of 
apocynin on vascular inflammatory activity and thrombogenicity.  It is 
important to realize that a non-invasive method to assess vascular 
inflammation in vivo would be important in preclinical research for rapid, high 
throughput non-invasive assessment of drug effects. 
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3. Methods and material !
3.1 Factors affecting the endothelial retention of targeted 
microbbles: influence of mirobubble shell design and cell 
surface projection of the endothelial target molecule. 
 
Elham Khanicheh MD, Martina Mitterhuber MSc, Katharina Kinslechner MSc, 
Lifen Xu PhD, Jonathan R. Lindner MD, Beat A. Kaufmann MD. 
Journal of American Society of Echocardiography. 2012 Apr; 25(4):460-6!!
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3.2 Noninvasive ultrasound molecular imaging of the effects 
of Statins on endothelial inflammatory phenotype in early 
atherosclerosis. !
Elham Khanicheh MD, Martina Mitterhuber MSc, Lifen Xu PhD,    Stéphanie 
P. Haeuselmann MSc, Gabriela M. Kuster MD, Beat A. Kaufmann MD  
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3.3 Rapid reduction of endothelial activation in early- stage 
atherosclerosis with apocynin independent of anti- oxidative 
properties. 
 
Elham Khanicheh MD, Yue Qi MD, Aris Xie BS, Martina Mitterhuber MSc, 
Lifen Xu PhD, Michika Mochizuki PhD, Youssef Daali PhD, Vincent Jaquet 
PhD, Karl-Heinz Krause MD, Zaverio Ruggeri MD, Gabriela M. Kuster MD, 
Jonathan R. Lindner MD, Beat A. Kaufmann MD !!!!!!!!!!!!!!!!!!
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OBJECTIVE: Anti-oxidative drugs continue to be developed for the treatment of 
atherosclerosis.  Apocynin is an NADPH-oxidase-inhibitor with anti-inflammatory 
properties. We used contrast enhanced ultrasound (CEU) molecular imaging to assess 
whether short-term apocynin therapy in atherosclerosis reduces vascular oxidative 
stress and endothelial activation  
APPROACH AND RESULTS: Genetically-modified mice with early 
atherosclerosis were studied at baseline and after 7 days of therapy with apocynin 
(4mg/kg/d I.P.) or saline. CEU molecular imaging of the aorta was performed with 
microbubbles targeted to vascular cell adhesion molecule 1 (VCAM-1; MBV), to 
platelet GP1bα (MBPl), and control microbubbles (MBCtr). Aortic VCAM-1 was 
measured using Western Blot. Aortic ROS generation was measured using a 
lucigenin assay. Hydroethidine (HE) oxidation was used to assess aortic superoxide 
generation. 
Baseline signal for MBV (1.3±0.3 A.U.) and MBPl (1.5±0.5 A.U.) was higher than for 
MBCtr (0.5±0.2 A.U., p<0.01). In saline-treated animals, signal did not significantly 
change for any microbubble agent whereas short-term apocynin significantly 
(p<0.05) reduced VCAM-1 and platelet signal (MBV: 0.3±0.1,  MBPl: 0.4±0.1  MBCtr: 
0.3±0.2 A.U., p=0.6 between agents).  Apocynin reduced aortic VCAM-1 expression 
by 50% (p<0.05).  However, apocynin therapy did not reduce either ROS content, 
superoxide generation, or macrophage content.. 
CONCLUSIONS: Short-term treatment with apocynin in atherosclerosis reduces 
endothelial cell adhesion molecule expression.  This change in endothelial phenotype 
can be detected by molecular imaging before any measurable decrease in macrophage 
content, and is not associated with a detectable change in oxidative burden. 
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INTRODUCTION 
Endothelial activation is a key step both in the initiation of atherosclerotic lesions 
as well as in their progression to a late stage, where inflammatory cell burden and 
susceptibility to acute atherothrombotic complications are high.  Oxidative stress 
plays a major role in supporting and amplifying the endothelial activation in 
atherosclerosis1.  The family of NOX NADPH oxidase present in plaque 
macrophages, and in native endothelial and smooth muscle cells is a major source of 
reactive oxygen species (ROS) and therefore represents a potential therapeutic target 
2. 
 Apocynin is a polyphenolic drug that has been isolated from plant extracts 
and inhibits assembly of the NOX2 isoform of the NADPH oxidase enzyme 
complex3.  In mice with advanced atherosclerosis, long-term therapy with apocynin 
has been shown to reduce endothelial adhesion molecule expression, platelet 
adhesion, and plaque growth; while in hypercholesterolemic rabbits apocynin started 
at a much earlier stage of disease has been shown to prevent development of 
atherosclerotic lesions 4.  It is unknown whether the beneficial effects of apocynin 
occur early after initiation of therapy.  With regards to mechanism, it is unknown 
whether apocynin’s effects are entirely due to a reduction in oxidative stress since 
polyphenolic drugs such as apocynin have anti-inflammatory effects independent of 
their anti-oxidant properties 5, 6.  Direct anti-inflammatory action independent of anti-
oxidant properties has been substantiated by the reduced adhesion molecule 
expression in cultured endothelial cells exposed to apocynin 7, 8. 
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In this study we addressed many of these knowledge gaps.  We performed in vivo 
ultrasound molecular imaging to test the hypothesis that short-term administration of 
apocynin in a model of early atherosclerosis reduces endothelial activation and 
platelet adhesion, two factors that are recognized to play an important role in plaque 
progression.  Ex vivo techniques were used to evaluate whether these effects were 
associated with a reduction in vessel oxidative stress. 
METHODS 
Mouse Model and Experimental Setup 
All experiments were performed in accordance with Swiss Federal Legislation and 
with the Guide for the Care and Use of Laboratory Animals of the National Institute 
of Health, and were approved by the local Animal Care and Use Committee at 
Oregon Health & Science University and the Animal Care Committee of the Canton 
of Basel.  Male mice with a double knockout for the LDL receptor and the Apobec-1 
editing enzyme on a C57Bl/6 background were used. These mice develop 
atherosclerosis in a predictable, age-dependent fashion while on a normal chow diet.  
At 20 weeks of age, when the mouse model shows lesions that cover about 5% of the 
total aortic surface, and small fibrofatty lesions can be seen on histology 9, the mice 
were treated with either apocynin (4mg/kg/d; acetovanillone, Sigma) (n=40) or 0.9% 
saline (n=40) daily by intraperitoneal route.  Animals were studied after 7 d of 
therapy.  A small subset of animals (n=6 for each treatment group) was also studied 
before initiation of therapy. For each imaging study aortic contrast-enhanced 
ultrasound for endothelial adhesion molecule expression and platelet adhesion was 
performed.  Assessment of aortic oxidative stress, VCAM-1 expression and platelet 
adhesion were performed by a panel of histologic and tissue assay techniques. 
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Microbubble Preparation 
Biotinylated, lipid-shelled decafluorobutane microbubbles were prepared by 
sonication of a gas saturated aqueous suspension of distearoylphosphatidylcholine 
(2mg/ml; Avanti Polar Lipids, Alabaster AL), polyoxyethylene-40-stearate (1mg/ml; 
Sigma), and 1,2-distearoyl-sn-glycero-phosphoethanolamine-N-
[biotinyl(polyethylene glycol)-2000] (0.1mg/ml, Avanti Polar Lipids, Alabaster AL). 
Microbubbles targeted to VCAM-1 (MBVCAM) were prepared by conjugation of 
biotinylated rat anti-mouse VCAM-1 antibody (MK 2.7) to the microbubble surface 
using biotin-streptavidin-biotin linking as previously described 10.  Microbubbles 
targeted to GP1ba  on activated platelets (MBPl) were prepared by conjugating a 
biotinylated dimeric recombinant A1 domain (amino acids 445 to 909) of mouse von 
Willebrand factor (vWF) to the microbubbles.  It has been shown previously that 
these microbubbles attach specifically to stationary platelet complexes even at high 
shear rates and that competitive inhibition from plasma vWF, or interaction with 
circulating platelets is minimal 4.  Control microbubbles (MBCtr) bearing a non-
specific isotype control antibody (R3-34, BD Bioscience) were also prepared.  
Microbubble concentration and size were measured by electrozone sensing 
(Multisizer III, Beckman- Coulter).  Microbubble mean size was not statistically 
different for the three microbubble preparations (2.8±0.2 for MBCtr, 2.8±0.2 for 
MBVCAM, 2.9±0.2 for MBPl). 
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Contrast Enhanced Ultrasound Molecular Imaging 
Ultrasound imaging (Sequoia Acuson C512; Siemens Medical Systems USA Inc., 
Mountain View, CA) was performed with a high-frequency linear-array probe (15L8) 
held in place by a railed gantry system.  The ascending aorta including the sinus of 
valsalva of the mouse was imaged in a long axis plane from a right parasternal 
window.  Contrast enhanced ultrasound (CEU) was performed with power 
modulation and pulse inversion (Contrast Pulse Sequence) imaging at a centerline 
frequency of 7 MHz and a dynamic range of 50 dB.  The gain settings were adjusted 
to levels just below visible noise speckle and held constant. MBVCAM, MBPl or MBCtr 
(1x106 microbubbles per injection) were injected intravenously in random order.  
Ultrasound imaging was paused from the time of injection until eight minutes later 
when imaging was resumed at a mechanical index of 0.87.  The first acquired image 
frame was used to derive the total amount of microbubbles present within the aorta.  
The microbubbles in the ultrasound beam were then destroyed with several (>10) 
image frames.  Several image frames at a long pulsing interval (10 sec) were 
subsequently acquired to measure signal attributable to freely circulating 
microbubbles. Data were log-linear converted using known dynamic range lookup 
tables, and frames representing freely circulating microbubbles were digitally 
subtracted from the first image to derive signal from attached microbubbles alone.  
Contrast intensity was measured from a region of interest encompassing the sinus of 
valsalva, the ascending aorta and the initial portion of the aortic arch, extending into 
the origin of the brachiocephalic artery.  The selection of the region of interest was 
guided by fundamental frequency anatomic images of the ascending aorta acquired at 
14MHz at the end of each individual imaging sequence. 
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Echocardiography 
High frequency (30MHz) ultrasound imaging (Vevo 770, Visual Sonics 
Inc.,Toronto, Canada) was performed for assessment of cardiac function.  M-Mode 
images of the left ventricle at the height of the papillary muscles were used to 
calculate ejection fraction.ref   The aortic arch was imaged to measure internal 
diameter and the centerline aortic peak flow velocity in the same location was 
measured on pulsed-wave spectral doppler tracing as an index of aortic shear. 
 
Assessment of VCAM-1 and Plaque Macrophage Content 
VCAM-1 expression was assessed in four apocynin-treated and four saline-treated 
animals by Western blot and histology.  For Western blot, the ascending portion of 
the aorta was homogenized in lysis buffer (Cell Signaling) containing 80mmol/L 
Pefabloc SC plus (Roche). Protein concentration was measured using the Micro BCA 
(bicinchoninic acid) protein assay kit (Thermo Scientific). Ten microgram of protein 
were resolved on SDS-PAGE and transferred to Polyvinylidene fluoride (PVDF) 
membranes (Amersham). Membranes were probed with monoclonal rat anti-mouse 
VCAM-1 (Clone # 112702, R&D Systems) and monoclonal anti-α-tubulin (Clone 
DM1A, Sigma) antibodies. Blots were subsequently incubated with horseradish 
peroxidase-conjugated secondary antibodies (Jackson Immuno Research) and band 
intensities were detected by enhanced chemiluminescence (Western Lightening Plus; 
Perkin Elmer) and quantitated using NIH ImageJ software (http://rsbweb.nih.gov/ij/).   
Fluorescent immunohistochemistry was performed to spatially characterize the 
endothelial expression of VCAM-1 and to quantify plaque macrophage content.  
Frozen aortic sections were mounted on glass slides, fixed in -20°C Acetone, air-
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dried, blocked with 10% goat serum in TBS/FSGO and incubated overnight at 4°C 
with monoclonal rat anti-VCAM-1 (CBL-1300, Millipore) and then for 1 hour at 
room temperature with goat anti-rat Alexa-633 (A21094, Invitrogen). Subsequently, 
Macrophages were labeled with a biotinylated rat anti Mac-2 (125403, Biolgegend).  
Fluorescent labeling of anti Mac-2 was accomplished with Alexa-594 labeled 
streptavidin (016-580-084, JacksonImmunoResearch).  Sections were mounted with 
Prolong gold antifade mounting medium containing DAPI and imaged on a Zeiss 
LSM 710 confocal microscope. Alexa-633 representing VCAM-1 was detected with 
an excitation wavelength of 633nm and an emission wavelength of 650-740nm and 
Alexa594 representing Mac 2 with 594 excitation wavelength and 580-630 emission 
wavelength. Exposure time, averaging, and laser intensity were kept constant for all 
images.  For spatial quantification of plaque macrophage content, the number of 
positively stained pixels was counted on threshold pictures and normalized to the 
total number of pixels of the plaque using Image-J. Thresholds were defined as the 
mean background intensity plus 40 times the standard deviation in each individual 
picture. For each mouse at least two cross-sections on different slides were imaged 
and quantified for both the base and ascending aorta. 
 
Assessment of endothelial platelet adhesion 
After the termination of imaging experiments, apocynin-treated and non-treated 
mice (n=5 each) were injected intravenously with 50µg rhodamine-6G (Sigma 
Aldrich).  Ten minutes after injection, a right atrial incision was made through an 
anterior thoracotomy.  The blood volume was removed with 10 ml of 37°C phosphate 
buffered saline through a left ventricular puncture at an infusion pressure ≤100 mm 
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Hg. The ascending aorta was then carefully removed, incised longitudinally, and 
pinned endothelial side facing up for en face fluorescent microscopy (×20 objective) 
with epi-illumination at an excitation wavelength of 490nm.  The degree of 
platelet/leukocyte complex attachment to the endothelium was quantified in 20 
randomly selected non-overlapping visual fields by thresholding at >10 SD above 
normal endothelial surface with Image-J (National Institutes of Health, Bethesda, 
MD) and expressing area with positive fluorescence normalized to total endothelial 
surface area. 
 
NADPH oxidase activity and superoxide anion production 
For the assessment of NADPH oxidase activity, a right atrial incision was made 
through an anterior thoracotomy.  The blood volume was removed with 10 ml of 37° 
C phosphate buffered saline through a left ventricular puncture at an infusion pressure 
≤100mmHg.  The ascending aorta was carefully removed and cut into three circular 
segments of equal length, and the wet weight of the individual segments was 
measured. Aortic rings were incubated with 85µL of Jude Krebs Buffer (119mM 
NaCl, 20mM HEPES, 4.6mM KCl, 1mM MgSO4, 0.15mM Na2HPO4.2H2O, 0.4mM 
KH2PO4, 5mM NaHCO3, 1.2mM CaCl2, 5.5mM Glucose) containing protease 
inhibitor (Roche) at 37°C for 30 min. NOX activity was measured with a 
luminescence assay in a microplate luminometer with 2.5µL DMSO, 10µM lucigenin 
(Sigma) and 100µM NADPH (Sigma) per well (final volume 100uL/well). Data were 
recorded as relative light units over time, and integrated and calculated as area under 
the curve using Image J software for statistical analysis.  
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For measurement of superoxide (O2.-) anion production, the aortas were removed 
as described above.  The ascending aorta was dissected, cleaned from surrounding 
tissue and cut into rings of approximately 3 millimeters. The rings were incubated 30 
minutes in 300 µl HBSS (Invitrogen) containing 50µM Hydroethidine (HE) (Sigma 
Aldrich) at 37°C in the dark. The rings were then washed in phosphate buffered 
saline, snap frozen and kept at -80°C. The day of the experiment, the rings were 
homogenised in 370 µl methanol. The homogenate was centrifuged at 13,000 rpm for 
5 min and 50 µl of supernatant was used for protein quantification using BIO-RAD 
protein assay (Bio-Rad Laboratories GmbH, München) while the rest was dehydrated 
using a speed vacuum concentrator. The resulting pellet was dissolved in 100 µL H2O 
for HPLC analysis (1100 Series (Agilent, Palo Alto, Ca). Hydroethidine and its two 
oxidized products, i.e., superoxide-specific 2-hydroxyethidium and ethidium 11 were 
separated by HPLC equipped with a fluorescence detector with excitation at 510 nm 
and emission at 595 nm. The area under EOH peak was calculated and values were 
normalized to protein content of the rings. 
 
Statistical Analysis 
Data were analyzed on GraphPad Prism (version 5.0d).  Data are expressed as 
mean±SEM unless stated otherwise.  Single comparisons between the two animal 
groups were performed with a Mann-Whitney test.  Kruskal-Wallis ANOVA with 
Dunn’s post hoc test was used to compare microbubble signals within and between 
animal groups.  For assessing the effect of treatment on targeted signals in the 
subgroup of animals that were imaged before and after treatment, a Wilcoxon 
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matched-pairs signed rank test was used.  A p value <0.05 (2-sided) was considered 
statistically significant. 
 
RESULTS 
Effect of apocynin on VCAM-1 expression and endothelial platelet adhesion 
Apocynin treatment for 1 week reduced total aortic wall expression of VCAM-1 
on Western blot by 50% (Figure 1A).  On immunohistochemistry, small regions of 
neointimal formation were observed in the aortic root and proximal ascending 
portion.  VCAM-1 staining was present on the endothelial lining and on macrophages 
in fibrofatty lesions in non-treated animals. In apocynin-treated animals, VCAM-1 
expression was reduced both on endothelial cells as well as on macrophages within 
lesions, while the total amount of macrophages present in plaques remained 
unchanged (Figure 2).  The reduction in endothelial VCAM-1 expression was evident 
both in regions overlying plaques as well as on endothelium in regions without 
plaques (Figure 1B-E). 
In vivo labeling of platelets with rhodamine-6G allowed visualization of 
platelet/leukocyte aggregates on the vascular endothelial surface.  Platelet/leukocyte 
aggregates were present in regions with early plaques, but also in regions of the aortic 
endothelial surface with a normal appearance.  Both the number of platelet/leukocyte 
aggregates per square millimeter (0.33±0.065 in apocynin treated animals vs 
0.62±0.065 in non-treated animals, p<0.01) and the percentage of endothelial surface 
covered by platelet/leukocyte aggregates was significantly reduced in animals that 
were treated with apocynin (Figure 3). 
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Effect of apocynin on vascular oxidative stress 
Lucigenin assays showed robust NADPH oxidase activity in whole aortic rings of 
non-treated mice. In mice treated with apocynin, NADPH-dependent lucigenin 
chemiluminescence was not different compared to non-treated mice.  Given the 
potential of lucigenin to undergo redox cycling and generate artifactual signals, high 
pressure liquid chromatography (HPLC) of tissue extracts after exposure of aortic 
rings to HE was performed to directly assess tissue superoxide content. In accordance 
with the results of the lucigenin assays, DHE oxidation to EOH was not different 
between the two animal groups (Figure 4).   
 
Molecular Imaging of VCAM-1 expression and platelet adhesion 
High frequency ultrasound imaging was not of sufficient quality for evaluation in 
one animal in each group.  In the remaining animals, there were differences in left 
ventricular ejection fraction, peak aortic flow velocity or aortic diameter, indicating 
that apocynin treatment did not lead to hemodynamic differences that could 
potentially influence targeted microbubble adhesion (table). 
CEU molecular imaging in the ascending aorta at baseline showed greater signal 
enhancement for VCAM-1-targeted and platelet-targeted microbubbles compared to 
control microbubbles (Figure 5).  After 7 days of treatment with apocynin, signal for 
VCAM-1 targeted and platelet targeted microbubbles was not different from control 
microbubble signal (Figure 5).  In contrast, in animals treated with saline injections, 
the signal for VCAM-1 and platelets was elevated significantly over control signal to 
a degree that was similar to baseline.  In the subgroup of animals that were imaged 
before and after treatment, apocynin lead to a significant decrease in VCAM-1 
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targeted signal (from 1.80±0.51 to 0.30±0.10, p=0.046) and a strong trend for 
decrease in platelet-targeted signal (2.21±0.80 to 0.35±0.07, p=0.078).  In animals 
imaged before and after treatment with saline injections, signal for VCAM-1 (1.44± 
0.55 vs. 1.00± 0.23, p=1.00) and platelet-targeted signal (1.84± 0.88 vs. 1.26± 0.40, 
p=0.69) did not decrease significantly.  
 
DISCUSSION 
Endothelial activation plays a crucial role in the initiation and progression of 
atherosclerotic plaque formation.  In this study, short term treatment with the 
polyphenol apocynin in a murine model of early mild atherosclerosis leads to a 
reduction in endothelial inflammatory phenotype and platelet adhesion.  These 
relatively acute changes were not associated with a measurable reduction in vascular 
NADPH oxidase activity or superoxide content.  
Endothelial adhesion molecule expression is an early and important step in the 
pathogenesis of atherosclerosis.  Deposition of oxidized LDL in the vascular wall 
leads to endothelial expression of pro-inflammatory cytokines such as IL-1-β and 
tumor necrosis factor-α.  Locally increased cytokine levels result in an upregulation 
of cell adhesion molecules such as VCAM-1, mediated by the transcriptional factors 
activated protein-1 (AP-1) and nuclear factor κB (NF-κB), this in turn promotes the 
recruitment of leukocytes to the vessel wall. 
ROS generated by NADPH oxidases both in endothelial cells as well as in 
leukocytes in nascent plaques are thought to amplify vascular inflammation 
throughout the pathogenesis of atherosclerosis.  Accordingly, mouse models with 
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knockouts of the NADPH oxidase isoforms NOX-1 and NOX-2 or the cytosolic 
NADPH oxidase subunit p47phox have shown a reduction in atherosclerotic plaque 
formation 12-14.  In humans, functional deficiency of the GP91phox subunit is 
associated with smaller carotid intima-media thickness (CIMT) 15.  These findings 
have generated interest in using inhibitors of NADPH oxidases for the treatment of 
atherosclerosis.  Apocynin inhibits NADPH oxidase activity in leukocytes allegedly 
by impeding the assembly of the cytosolic subunits at the cell membrane 16. In cell 
culture experiments it has been noted that the inhibitory action of apocynin occurs 
with a delay, suggesting that it has to undergo activation before inhibiting ROS 
generation.  In the presence of H2O2 and myeloperoxidase, apocynin is converted to 
an apocynin radical and subsequently forms apocynin dimers, which are thought to be 
the active compounds that result in inhibition of NADPH oxidase activity 17.  Thus, 
the effect of apocynin on NADPH oxidase inhibition during the later stages of 
atherosclerosis may depend on its activation in vascular tissue and require a sufficient 
inflammatory cell and oxidative stress burden.  Notably, however, apocynin also 
exerts anti-inflammatory effects that are independent of NADPH oxidase inhibition 6.  
Such effects may be of importance during the early stages of atherosclerosis, when 
inflammatory cell load and oxidative burden are low. 
We examined the effects of treatment with apocynin in a murine model of early 
atherosclerosis in mice with fibrofatty lesions.  Assessing treatment effects of 
potential drug candidates during the early stages of atherosclerosis is of clinical 
significance, since interventions that are started early during the pathogenesis of 
atherosclerosis are thought to afford a larger risk reduction for cardiovascular events 
than interventions that are initiated when clinical atherosclerotic disease is established 
18.  Our data indicate that treatment with apocynin results in a rapid decrease in 
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endothelial expression of VCAM-1.  These results are in line with observations in cell 
culture showing a decrease in VCAM-1 expression in response to apocynin 8, and 
extend observations made in advanced atherosclerosis to earlier stages of plaque 
development 4.  In addition, the observation that the decrease in vascular 
inflammation was not associated with a reduction of vascular NADPH oxidase 
activity or tissue superoxide content indicates that the antiinflammatory effect of 
apocynin observed in our study was probably mediated through a ROS-independent 
mechanism in the very early stages of atherosclerotic plaque development, possibly 
mediated instead by its effects on cytochrome P450 pathways19. 
In addition to endothelial cell inflammatory activation, platelet-endothelial 
interactions play a role in vascular inflammation and the pathogenesis of 
atherosclerosis.  Platelet-endothelial interactions mediated by P-Selectin and von 
Willebrand factor-GPIb ligation in the absence of plaque rupture accelerate plaque 
formation in murine atherosclerosis 20-22.  The interaction of activated platelets with 
the endothelial surface results in the secretion of proinflammatory cytokines CD40L 
and IL-1β, as well as of chemokines like RANTES (regulated on activation, normal T 
cell expressed and secreted) and platelet factor 4 (PF4) to the vascular wall, all of 
which facilitate increased monocyte recruitment 23-25.  Platelets from patients with 
functional deficiency of GP91phox subunit of NADPH oxidase or control subject 
platelets treated with apocynin have reduced in vitro platelet recruitment and 
aggregation, indicating a direct role of NADPH oxidase in platelet reactivity 26.  Our 
molecular imaging results indicate a decrease in platelet-endothelial interactions after 
treatment with apocynin.  While we did not specifically investigate the pathways 
responsible for the action of apocynin in platelets, previous data indicate that 
apocynin influences platelet aggregation by mechanisms that are dependent on 
! 67!
NADPH oxidase activity 27 but also on changes in arachidonic acid metabolism with 
a decrease in thromboxane A2 formation 5. 
Several limitations of our study deserve attention.  First, as the aim of our study 
was to assess the acute effects of apocynin treatment on the endothelial inflammatory 
phenotype, we did not expect an influence of treatment on plaque size and thus did 
not perform histological analysis.  However, long-term treatment with apocynin has 
been shown to reduce plaque formation in our mouse model 5.  Also, the dose used in 
our study was in the low range of doses used in published animal studies, however, 
there is no established optimal dose, and our data demonstrate an effect of the 
treatment on both endothelial inflammatory phenotype and platelet adhesion.  
Furthermore, while we applied well-established techniques to measure NADPH 
oxidase activity and superoxide content without finding an effect of apocynin 
therapy, we cannot exclude that locally restricted (e.g. endothelial) and/or changes in 
other ROS species contributed to the observed effect.  Finally, our methods for 
evaluating platelet adhesion did not allow differentiation of direct endothelial 
attachment and platelet-monocyte complexes. 
In summary, we show that in a murine model of early atherosclerosis, treatment 
with apocynin leads to a rapid decrease in endothelial inflammation and platelet 
adhesion.  Our data indicate that these effects of apocynin are not associated with a 
measurable decrease in ROS generation. 
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FIGURES 
!
Figure'1.! Assessment' of' VCAM41' expression' after' 7' days' of' saline' or'
apocynin'treatment.'
(A) VCAM01! protein! expression! in! the! ascending! aorta! assessed! by!Western!blot!in!non0treated!(lanes!104)!versus!apocynin0treated!(lanes! 508)! animals,! n=! 4! per! group,! *! p<! 0.05! vs! non0treated!animals.! ! Representative! examples! of! fluorescent!immunohistochemistry! images! of! the! base! of! the! aorta!demonstrating! endothelial! VCAM01! expression! (red!fluorescence)! in! a! non0treated! animal! at! 100fold! magnification!
(B),!in!the!same!animal!at!400fold!magnification!(C)!and!reduced!VCAM01!expression!in!an!apocynin0treated!treated!animal!(D,'E).!Autofluorescence!delineating!vessel!anatomy! is!shown! in!green,!DAPI!staining!of!the!nuclei!in!blue.!
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'
Figure'2.' Assessment'of'plaque'macrophage'content'after'7'days'of'saline'
or'apocynin'treatment.'
! (A)!Percentage!of!the!plaque!area!covered!with!macrophages!(Mac02!staining)!at!the!base!of!the!aorta!and!in!the!ascending!aorta!(n=8!in!each!group;!p=ns!vs!non0treated).!(B)!Example!of!trans0illumination!image! used! for! plaque! delineation.! (C)! Example! of! Mac02! staining!used!for!quantification!of!macrophage!content!in!the!plaque.!
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'
Figure'3.! Assessment' of' platelet' adhesion' on' the' aortic' endothelial'
surface'after'7'days'of'saline'or'apocynin'treatment.!
(A)! Percentage! of! the! endothelial! surface! of! the! ascending! aorta!covered!with!platelet/leukocyte!aggregates!(n=5!in!each!group),!*!p<!0.05! vs! non0treated! animals.! ! Examples! of! en! face! fluorescence!microscopy! demonstrating! two! platelet/leukocyte! aggregates! on!normal! appearing! endothelial! surface! in! a! non0treated! animal! (B)!and!absence!of!platelet/leukocyte!aggregates!in!an!apocynin0treated!animal!(C).!Scale!bar!=!25!µm!
'
'
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'
Figure'4.' Assessment'of'ROS'generation'after'7'days'of'saline'or'apocynin''''
treatment.'
(A)! Superoxide0generating! activity! of! whole! aortic! rings! after! the!addition! of! 100!µM!NADPH! at! 4!minutes.! Measurements! represent!relative!light!units!(RLU).!p=ns!between!saline0treated!and!apocynin0treated! animals! (n=10! in! each! group).! (B)! HPLC! analysis! of! EOH!generated! in! vascular! rings! exposed! to! 50µM! DHE.! p=ns! between!saline0treated!and!apocynin0treated!animals!(n=8!in!each!group).'
'
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'
Figure'5.! Molecular' imaging' of' the' ascending' aorta' before' the' start' of'
treatment.'
(A)' Mean' ±! SEM! background0subtracted! signal! intensity! for!microbubbles! targeted! to!VCAM01! (MBVCAM),! to!GP1bα ! on!activated!thrombocytes!(MBPl)!!and!control!microbubbles!(MBCtr).!*!p<!0.01!vs!MBctr,!#!p<0.05!vs!MBctr!(n=12).!Examples!of!color!coded!CEU!images!after!injection!of!MBCtr!(B),!of!MBVCAM!(C)!and!of!MBPl!(D).!The!color!scale!for!the!CEU!images!is!shown!at!the!bottom!of!each!frame.!!
!
!
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!
Figure'6.! Molecular' imaging'of' the'ascending'aorta'after'7'days'of'saline'
or'apocynin'treatment.'
(A)' Mean' ±! SEM! background0subtracted! signal! intensity! in! saline0treated!(n=9)!and!apocynin0treated!(n=10)!animals!for!microbubbles!targeted! to!VCAM01!(MBVCAM),! to!GP1bα !on!activated! thrombocytes!(MBPl)!!and!control!microbubbles!(MBCtr).!*!p<!0.01!vs!MBctr,!#!p<0.01!vs! MBctr.! ¶! p<0.05! vs! the! same! microbubble! in! apocynin! treated!animals.!
Examples!of! color! coded!CEU! images! after! injection!of!MBCtr! (B),! of!MBVCAM! (C)! and! of!MBPl! (D)' in! saline! treated! animals.! ! In! the! same!
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order,! examples! of! color! coded! CEU! images! after! injection! of!MBCtr!
(E),! of!MBVCAM! (F)! and!of!MBPl! (G)' in! apocynin! treated! animals! are!shown.!
!
!
Table.!Echocardiographic!data!(mean!±!1!SD)!
'
Saline4
treated'
(n=8)'
Apocynin4
treated'
(n=9)'
P4'value'
Ejection'fraction'(%)' 58.4±13.1' 61.6±8.8' ns'
Aortic'internal'diameter'(mm)' 1.54±0.09' 1.50±0.12! ns'
Aortic' peak' systolic' velocity'
(m/s)' 0.58±0.15' 0.68±0.03' ns'!
!!!!!!!!!
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4. Discussion 
 
4.1 The influence of the length of functionalized polyethylene 
glycol spacer arms on improving the targeting efficiency of 
microbubbles 
 
In recent years CEU molecular imaging has been used to non- invasively 
assess the pathophysiology of diseases at the molecular level. Lipid or 
albumin shell microbubbles with a heavy gas core are used as contrast agent. 
Imaging of the molecular footprints of the disease requires specific 
attachment of microbubbles to the molecule of interest. Therefore, for the 
specific targeting of microbubbles functionalized PEG spacer arms are also 
incorporated into the microbubble shell. 
It has been shown that the targeting efficiency of microbubbles is low with 
retention of less than 5% of targeted microbubbles under high flow shear rate 
(54). In the present work we studied the influence of the length of PEG spacer 
arm on targeting efficiency of microbubbles. The improvement of targeting 
efficiency of microbubbles is also highly important where the targeted 
molecule is a relatively short molecule and is hidden in the glycocalyx.  
Our study demonstrated that microbubbles with a longer PEG spacer arm 
yield a better targeting efficiency compared to the microbubbles with a shorter 
PEG spacer arm. In addition, reduced accessibility to the endothelial target 
due to the thickness of glycocalyx in the vessels may have an important 
influence on microbubble attachment.  
The improvement of the targeting efficiency of microbubbles with longer PEG 
spacer arm could be due to better accessibility of the conjugated ligands on 
the microbubble surface to their endothelial target. In addition, bonds formed 
between ligands presented by longer PEG spacer arms to their target are 
more stable under flow condition. This can be explained by localizing the 
bond structure at the trailing point of the microbubble thus reducing torque 
forces exerted on the microbubbles under flow conditions (55). 
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Interaction of targeted microbubbles with their endothelial target occurs in the 
presence of the endothelial glycocalyx.  The glycocalyx could hinder ligand- 
counter ligand bond formations leading to lower signal obtained from 
microbubbles targeted to relatively short molecules hidden in the glycocalyx. 
Thus the low signal obtained when targeting the short cell adhesion molecule 
ICAM-1 could be secondary to glycocalyx steric hindrance or charge 
repulsion. However, the microbubbles with a longer PEG spacer arm still 
provided a higher ultrasound signal, possibly through increasing the chance 
of microbubble adhesion by projecting their ligands close enough to the 
endothelial surface for bond formation. In addition, degration of the glycocalyx 
resulted in an improvement of signal for microbubbles with different PEG 
spacer arm lengths. 
 
4.2 noninvasive ultrasound molecular imaging of the effect of 
statins on endothelial inflammatory phenotype in early 
murine atherosclerosis 
 
Atherosclerosis is a chronic inflammatory disorder and hence in recent years 
there has been a great interest in developing therapeutic regimes that target 
inflammatory pathways. Endothelial expression of the inflammatory molecule 
Vascular Cell Adhesion Molecule- 1 (VCAM-1) plays an important role in the 
initiation and progression of atherosclerosis. Improved strategies for 
atherosclerosis treatment require development of novel noninvasive imaging 
technologies that assess the effects of treatment on vascular inflammation. 
Statins have been used for the treatment of atherosclerosis. Their preventive 
effect is not only due to their potential in lowering plasma LDL cholesterol 
levels but also due to their anti- inflammatory effects.  In the present study we 
investigated whether in vivo ultrasound molecular imaging of the expression 
of VCAM-1 could be used to assess the effects of statins on vascular 
endothelial phenotype in a mouse model of early atherosclerosis.  
We could show that CEU molecular imaging can assess the impact of therapy 
on endothelial inflammation in a murine model of early atherosclerosis. In 
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contrast high frequency ultrasound imaging of the aortic wall was unable to 
show effects of treatment on the atherosclerotic plaques.  
It has been previously shown that targeted contrast based MRI and SPECT 
molecular imaging are cable of assessing the effects of statin treatment in 
animal models of advanced atherosclerosis. However, in the current study we 
provided evidence that CEU molecular imaging is capable of detecting 
changes in endothelial phenotype due to pharmacologic treatment in the very 
early stages of the atherosclerosis pathogenesis.  An advantage of CEU 
molecular imaging is that it is capable of detecting targets specifically on the 
endothelial surface, whereas MRI and SPECT use diffusible tracers that need 
to accumulate in high concentrations both on the endothelial surface and 
within the plaque to be visualized. Therefore, given that phenotypic changes 
on the endothelial surface are responsible for the initiation of atherosclerosis, 
this method could be used not only to detect the initial phases of 
atherosclerosis pathogenesis but also for assessing treatment effects during 
the initial stages of atherosclerosis.   
In our study the lower signal for microbubbles targeted to VCAM-1 on CEU 
molecular imaging of the ascending aorta in statin treated animals, was 
associated with a decrease in VCAM-1 expression and also a reduction in 
inflammatory cell content of atherosclerotic plaques. We also assessed aortic 
wall thickness with conventional high frequency ultrasound imaging. Although 
there was a difference of 40µm in aortic wall thickness on histology between 
the two groups of animals, high frequency ultrasound imaging with a 
theoretical axial resolution in the same range was unable to detect effects of 
treatment. Therefore at a time point where conventional ultrasound imaging 
was unable to detect early effects of treatment, non- invasive ultrasound 
molecular imaging of the aorta was able to detect effects of treatment on 
endothelial inflammation. 
 
 
! 83!
4.3 The short-term effects of treatment with apocynin on 
endothelial inflammation - application of ultrasound 
molecular imaging 
 
Endothelial activation is a key step both in initiation and progression of 
atherosclerosis. Oxidative stress plays an important role in supporting and 
intensifying endothelial activation. A major source of reactive oxygen species 
(ROS) is NADPH oxidase (NOX) in macrophages inside plaques as well as 
endothelial and smooth muscle cells. Apocynin is a polyphenolic drug that 
inhibits assembly of NOX complexes at the cell membrane. The beneficial 
effects of apocynin have been attributed to its anti-oxidative and anti- 
inflammatory properties. However it is not yet clear whether these effects are 
present early in the development of atherosclerosis and with short term 
treatment. Thus in this study we used CEU molecular imaging to assess the 
short-term effects of apocynin on endothelial activation and investigated 
whether these anti-inflammatory effects are associated with reduced oxidative 
stress.  
We could show that short-term treatment with apocynin in a mouse model of 
early atherosclerosis results in reduced aortic endothelial inflammation 
presented as a reduced expression of endothelial VCAM-1 and platelet 
adhesion. However, these anti inflammatory effects were not associated with 
measurable vascular NADPH oxidase activity or superoxide content.  
These data are consistent with cell culture observations showing a decrease 
in endothelial VCAM-1 expression after exposure to apocynin and also in vivo 
studies after long-term treatment with apocynin in a mouse model of 
advanced atherosclerosis. However, the observed anti inflammatory 
response to apocynin in our study was not secondary to reduced NADPH 
oxidase activity or tissue ROS contents. The effects of apocynin are probably 
due to ROS- independent mechanisms in the early stages of atherosclerotic 
plaque development.  
Adhesion of activated platelets to vascular endothelium can recruit 
monocytes into the vessel wall by producing pro-inflammatory cytokines thus, 
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playing an important role in vascular inflammation and development of 
atherosclerosis. Our findings from CEU molecular imaging demonstrated that 
there is less attachment of activated platelets to aortic endothelial cells after 
treatment with apocynin. Although we did not investigate responsible 
pathways, previous studies indicate that apocynin influences platelet 
aggregation by different mechanisms involving NADPH oxidase activity and 
changes in arachidonic acid metabolism.  
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5. Abbreviations !
Ab  antibody 
Apo  apolipoprotein 
Apobec  apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 
CEU  contrast enhanced ultrasound 
CT  computed tomography 
dB  decibel 
F  frequency 
GP  glycoprotein 
HMG-CoA hydroxymethylglutaryl- coenzyme A 
ICAM  intracellular adhesion molecule 
IL  interleukin 
IVUS  intravascular ultrasound 
kPa  kilopascals 
LDL  low density lipoprotein 
MI  mechanical index 
MPa  megapascals 
MRI  magnetic resonance imaging 
mRNA  messenger ribonucleic acid 
NADPH nicotinamide adenine dinucleotide phosphate 
P  pressure 
PEG  polyethyleneglycol 
PET  positron emission tomography 
RBC  red blood cell 
ROS reactive oxygen species 
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SPECT  single photon emission computed tomography 
 
TNF  tumor necrosis factor 
TF  tissue factor 
TI  thermal index 
VCAM  vascular cell adhesion molecule 
vWF  von Willebrand factor 
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